Welcome to our dedicated page for Briacell Therapeutics Common Shares news (Ticker: BCTX), a resource for investors and traders seeking the latest updates and insights on Briacell Therapeutics Common Shares stock.
BriaCell Therapeutics Corp (NASDAQ: BCTX) is a pioneering biotechnology company headquartered in Los Angeles, specializing in the development of immunotherapy treatments for cancer management. The company’s innovative approach focuses on harnessing the body's immune system to target and eliminate cancer cells, providing new hope for patients battling this devastating disease.
Central to BriaCell's portfolio is the BriaVax vaccine, which has shown promising results in early-phase clinical trials. In two compelling FDA Phase I studies involving late-stage breast cancer patients, BriaVax demonstrated unique and unprecedented outcomes, showcasing its potential as a groundbreaking treatment. Building on these successes, BriaCell is aggressively advancing towards a Phase I/II clinical trial, aiming to expand its vaccine's application to a larger cohort of breast cancer patients.
In addition to BriaVax, the company is also developing Bria-IMT, currently in a Phase I/IIa clinical trial targeting metastatic breast cancer. Bria-IMT represents a targeted and safe approach to treating advanced-stage breast cancer, reinforcing BriaCell's commitment to innovative cancer therapies. Another significant development in their pipeline is the Bria-OTS ('off-the-shelf') personalized immunotherapy, designed to match the patient's HLA type, further customizing and enhancing the treatment's effectiveness.
While BriaCell's current focus remains on breast cancer, the company is exploring the potential of applying its vaccine technology to other cancer types, broadening its impact in the oncology field. With a strategic vision and robust pipeline, BriaCell is poised to make significant contributions to cancer treatment and patient care.
For more detailed updates and the latest news about BriaCell Therapeutics Corp, visit their website or contact them directly. The company remains committed to transparency and regularly shares progress on their groundbreaking research and clinical trials.
BriaCell Therapeutics Corp. (BCTX, BCTXW) has successfully repurchased 202,425 common shares and 70,246 warrants as part of its buyback program, aimed at enhancing shareholder value. The company is authorized to buy back up to 1,341,515 common shares and 411,962 warrants over the next 12 months. With a cash balance of US$57.3 million, BriaCell is well-positioned to advance its cancer immunotherapy strategies while executing this buyback. Additionally, Dr. William V. Williams, the CEO, will present at various upcoming conferences, underscoring the company's commitment to growth.
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) announces the addition of Suzanne Ostrand-Rosenberg, Ph.D. to its Scientific Advisory Board. Dr. Ostrand-Rosenberg boasts over 40 years of experience in cancer immunology and has contributed significantly to the understanding of the immune response to cancer. Her notable research includes work on CD4+ T-helper lymphocytes and myeloid-derived suppressor cells. The collaboration aims to enhance BriaCell's pipeline of immunotherapies, particularly for advanced breast cancer.
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) has appointed Dr. Jane Gross to its Board of Directors. With over 30 years of biotech experience, Dr. Gross has held significant roles at various companies, emphasizing her expertise in cancer therapeutics. The Board hopes to leverage her insights to advance BriaCell's immunotherapy pipeline. Additionally, the company granted stock options to Dr. Gross and its Scientific Advisory Board. BriaCell also announced a contract with North Equities Corp. for marketing and investor engagement purposes, costing CAD$105,000.
BriaCell Therapeutics Corp. (BCTX, BCTXW) recognizes October as Breast Cancer Awareness Month, highlighting the ongoing need for effective breast cancer treatments. The company, with $57 million cash as of July 31, 2021, continues its targeted immunotherapy program, achieving a notable 12-month overall survival benefit in trials and resolving a severe tumor in a patient. Additionally, BriaCell has initiated a securities buyback program to enhance shareholder value. The company emphasizes its commitment to treating patients beyond mere statistics.
BriaCell Therapeutics Corp. (BCTX, BCTXW) announces significant advancements in its immunotherapy for advanced breast cancer. In a recent interview, CEO Dr. Bill Williams highlighted a partnership with ImaginAb to assess the safety and efficacy of their treatments. The board has expanded to include corporate finance expert Marc Lustig, and the company plans to utilize over $55 million in excess capital for share repurchases. Dr. Williams emphasized the need to align the company’s valuation with its clinical progress, addressing concerns regarding its current market valuation.
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) has received approval from the TSX Venture Exchange for a normal course issuer bid (the “Buyback”). This allows the company to repurchase up to 1,341,515 common shares and 411,962 warrants over the next 12 months, starting September 28, 2021. This Buyback, managed by Independent Trading Group Inc., represents 10% of the public float as of September 21, 2021. The company assures that this initiative will not disrupt its growth plans in cancer immunotherapy and ongoing clinical trials.
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) will present at the Benzinga Healthcare Small Cap Conference on September 29-30, 2021. Dr. Bill Williams, President and CEO, is scheduled to speak at 1:15 PM ET on September 29. The event will be held virtually, and investors can register for a free spectator pass. BriaCell focuses on immunotherapies for advanced breast cancer, aiming to provide targeted treatment approaches. For more details, visit briacell.com.
BriaCell Therapeutics Corp. (BCTX, BCTXW) has authorized a repurchase program for up to 1,341,515 common shares and 411,962 warrants, representing 10% of the public float. With a cash balance of US$57 million as of July 31, 2021, the buyback is expected to enhance shareholder value. The Company is advancing its cancer immunotherapy pipeline, with key studies planned for 2022. The buyback will not interfere with BriaCell's growth initiatives in cancer treatments. Independent Trading Group will manage the repurchase program, which is subject to regulatory approvals.
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) announced the appointment of Marc Lustig to its Board of Directors, effective September 1, 2021. Lustig, a significant shareholder with 10% ownership through L5 Capital Inc., brings extensive experience in corporate finance and pharmaceuticals. He aims to enhance the company's capital markets strategy. The Board also approved a grant of 100,000 options to Lustig at C$7.24 per share, vesting immediately, with proceeds intended for donation to the Cedars Cancer Foundation.
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) will participate in the H.C. Wainwright 23rd Annual Global Investment Conference held virtually from September 13-15, 2021. Dr. William Williams, President & CEO, will outline the company's business during the presentation scheduled for September 13 at 7:00 A.M. (ET). Investors can access the presentation online through the provided link, with archived access for 90 days. BriaCell focuses on targeted immunotherapies for advanced breast cancer and is committed to innovative cancer management approaches.
FAQ
What is the current stock price of Briacell Therapeutics Common Shares (BCTX)?
What is the market cap of Briacell Therapeutics Common Shares (BCTX)?
What does BriaCell Therapeutics Corp do?
What are the main products of BriaCell Therapeutics Corp?
What is BriaVax?
What clinical trials is BriaCell currently conducting?
Where is BriaCell Therapeutics Corp headquartered?
Is BriaCell focusing only on breast cancer?
How can I contact BriaCell Therapeutics Corp?
What makes BriaCell's immunotherapy approach unique?
Who are the primary contacts for media and investor relations at BriaCell?
Where can I find the latest news about BriaCell Therapeutics Corp?
